Drug intelligence / Profile preview

GenePro

Development stage: Unknown
Lead developer: IGXBio
Modality: Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
Administration: Oral

Overview

GenePro is a DNA-based immunotherapy developed by IGXBio for the treatment of HIV/AIDS. It is designed to promote an anti-HIV immune response, aiming to address viral replication. The drug candidate has received FDA IND approval and is being investigated in collaboration with Cannabis Science to explore synergistic effects when combined with CS-TATI-1, a cannabinoid-based anti-inflammatory drug.

Brand names: GenePro

Beyond the preview

Go deeper on GenePro.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GenePro.

Explore the full profile